China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funds will be directed towards manufacturing plant construction, CDMO business expansion, new technology and process research and development, and manufacturing capacity expansion. This strategic financing round positions TinKer Bio for significant growth and innovation in the microfluidic chip sector.
Company Background and Capabilities
Founded in 2014, TinKer Bio has established itself as a pioneer in the transformation of microfluidic chips. The company is capable of converting microfluidic chips made from a variety of materials, including PMMA, PC, COC, PS, PP, PDMS, glass, and others, from design and development to mass production. Leveraging its full-chain microfluidic technology platform, TinKer Bio provides professional and comprehensive integrated solutions for microfluidic product design, development, production, and manufacturing.
Applications and Market Reach
TinKer Bio’s solutions are applicable across a broad range of industries, including medical in vitro diagnosis, organ chip technology, nano drug/material synthesis, and food safety/environmental protection detection. The company’s ability to offer end-to-end solutions positions it as a key player in the microfluidic chip market, addressing diverse and complex needs in various sectors.
Future Prospects
The Series A+ financing round is a significant milestone for TinKer Bio, providing the necessary capital to enhance its manufacturing capabilities and expand its CDMO business. With a focus on innovation and expansion, TinKer Bio is poised to make a substantial impact in the microfluidic chip technology space, driving forward the development of new applications and improving the efficiency and effectiveness of existing processes.-Fineline Info & Tech
